GLP-1 RA and DPP-4i are widely used to treat T2DM
Use of the semaglutide drugs has also been linked to increased risks of thyroid cancer, pancreatitis, and pancreatic cancer, hypoglycemia risks, acute kidney injury occurrences, gallbladder events, gastrointestinal disturbances, and cardiovascular effects
I can finally enjoy eating without guilt, and I listen to and respect the physical hunger cues I used to ignore
GLP-1 therapies can: Medication works best when combined with structured nutrition and activity coaching
The product supports blood sugar control by improving fasting blood sugar levels, postprandial glucose, glycated hemoglobin, and GLP-1 production
Dose adjustment considerations: If gastrointestinal symptoms are severe or persistent despite these measures, contact your prescribing clinician to discuss: Slowing the dose escalation schedule Temporarily reducing the dose Taking a brief treatment pause (though this may affect weight loss progress) Switching to an alternative weight management medication if symptoms are intolerable The STEP trials demonstrated that slower dose titration can reduce the incidence and severity of gastrointestinal adverse effects